AbbVie, Inc.

AbbVie, Inc.

AbbVie, Inc.

Overview
Date Founded

2013

Headquarters

1 North Waukegan Road North Chicago IL 60064-6400

Type of Company

Public

Employees (Worldwide)

30K

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

Contact Data
Trying to get in touch with decision makers at AbbVie, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Vice Chairman & President

Senior Vice President & Chief Financial Officer

Vice Chairman, External Affairs & Chief Legal Officer

Vice Chairman, Chief Commercial Officer

Vice President, Chief Ethics & Compliance Officer

Executive Vice President & Chief Human Resources Officer

Chief Strategy Officer & Executive Vice President

Executive Vice President-Operations

Vice President, Principal Accounting Officer & Controller

Board of Directors

Chief Executive Officer at AbbVie, Inc.

Former Chairman of the Board, President & Chief Executive Officer at United Airlines Holdings, Inc.

Chairman & Chief Executive Officer at 3M Interamerica, Inc.

Executive Vice President & Chief Administrative Officer at United Airlines, Inc.

President & Chief Executive Officer at Austin Investment Advisors

Former Director, President & Chief Executive Officer of the Company & the Bank at Northern Trust Corporation

Dean at Yale University - Yale School of Medicine

Director at Mine Safety Appliances Co. LLC

Former Director & Senior Vice President at The Boston Consulting Group, Inc.

Former President, Asia Pacific-Exploration & Production Company at Chevron Corp.

Paths to AbbVie, Inc.
Potential Connections via
Relationship Science
You
AbbVie, Inc.
Owners & Shareholders
Details Hidden

Capital World Global Investors (CWGI) is the investment adviser to the American Funds Group, a family of 30 funds marketed to individuals exclusively through financial advisers and other intermediaries. American Funds are also used as investment vehicles for 401ks, other retirement plans, variable annuities and 529 college savings plans. The funds have the following characteristics: (1) a long-term, value-oriented approach (2) long-established, global research (3) a multiple portfolio counselor system that combines teamwork with individual accountability (4) experienced, long-tenured investment professionals and (5) a commitment to low operating expenses, among the lowest in the fund industry. CWGI uses a Multiple Portfolio Counselor System. The assets of each fund are divided into smaller, more manageable portions. Each portion is managed by a portfolio counselor who operates autonomously, investing his or her portion as though it were an entire fund (subject to fund objectives and overall guidelines). Research analysts typically manage a segment as well, bringing their expertise directly to bear on the fund's results. Portfolio counselors are free to make their own decisions. As a fund's assets grow, new counselors can be added. Investment decisions are based on internal research. Equity research is comprehensive and bottom-up while at the same time constantly monitoring broader economic, political, currency and interest rate trends. Investment research is proprietary and used solely by CWGI portfolio managers.

Details Hidden

The Vanguard Group is an American investment management company based in Malvern, Pennsylvania, that manages approximately $3.4 trillion[1] in assets. It is the largest provider of mutual funds and now the second-largest provider of exchange-traded funds (ETFs) in the world after BlackRock, with about $451 billion in ETF assets under management, as of March 2015.[3] It offers mutual funds and other financial products and services to retail and institutional investors in the United States and abroad. Founder and former chairman John C. Bogle is credited with the creation of the first index fund available to individual investors,[4] the popularization of index funds generally,[5] and driving costs down across the mutual fund industry.

Details Hidden

SSgA FM's methods of analysis include quantitative, fundamental, technical, cyclical, indexing, arbitrage, charting and other strategy specific methods. They offer a broad range of strategies including: Active, Enhanced, and Passive Equity; Active & Passive Debt; Cash Management; Multi-Asset Class Solutions; Real Estate (including Direct Real Estate); Senior Loans; Managed Futures; and Private Equity. Active equity strategies include enhanced equity and active quantitative strategies. The strategies cover market-cap and style segments of the market including: large-cap core, large-cap growth, large-cap value, mid-cap, small-cap, small-cap value, all-cap, and long-short equity. They also manage long-short and long-short market neutral strategies. SSgA FM's Active & Passive Debt strategies offers a range of investment styles from passive to active, short to long duration, tax-exempt, sovereign to high yield, and single country to global. The firm's Cash Management strategies seek to generate current income while preserving capital and liquidity by investing in diversified portfolios of short-term securities. SSgA FM's Multi-Asset Class strategies employ an asset allocation model as means of diversification and seek to position assets among major investment categories. Their Multi Asset Class Solutions strategies employ an asset allocation model as a method of diversification that aims to position assets among major investment categories. SSgA FM's Managed Futures strategy allocates assets using two approaches: a managed futures strategy and a fixed income strategy. The firm's Private Equity strategies focus on rigorous partner selection, thorough evaluation of quality investment opportunities, and fundamental, research-driven research.

Recent Transactions
Details Hidden

AbbVie, Inc. purchases Allergan Plc

Details Hidden

AbbVie, Inc. purchases Stemcentrx, Inc. from Sequoia Capital, Western Technology Investment, The Founders Fund Management LLC, Artis Ventures Management LP

Details Hidden

AbbVie, Inc. raised money in a private placement transaction

Transaction Advisors
Investment Advisor

Advised onAbbVie, Inc. purchases Allergan Plc

Legal Advisor

Advised onAbbVie, Inc. purchases Pharmacyclics LLC

Legal Advisor

Advised onAbbVie, Inc. purchases Stemcentrx, Inc. from Sequoia Capital, Western Technology Investment, The Founders Fund Management LLC, Artis Ventures Management LP

Lender

Advised onAbbVie, Inc. purchases Pharmacyclics LLC

Lender

Advised onAbbVie, Inc. purchases Pharmacyclics LLC

Director

Advised onAbbVie, Inc. purchases Pharmacyclics LLC

Advisors & Consultants
Legal Advisor

Partner at Jones Day

Legal Advisor

Co-Chair, Product Liability Litigation Practice Group at Shook, Hardy & Bacon LLP

Legal Advisor

Partner at Latham & Watkins LLP

Clients

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Key Stats and Financials As of 2018
Market Capitalization
$114B
Total Enterprise Value
$175B
Earnings Per Share
$3.66
Revenue
$32.8B
Net Profit
$5.66B
EBITDAMargin
42.45%
Total Equity
$-8.45B
Total Debt
$40.3B
EBITDA
$13.9B
Enterprise Value Sales
5.34x
Enterprise Value EBITDAOperating
12.57x
TEVNet Income
30.9x
Debt TEV
0.23x
Three Year Compounded Annual Growth Rate Of Revenue
12.74%
Five Year Compounded Annual Growth Rate Of Revenue
11.75%
Political Donations
$750
2014
$1,000
2014
$750
2014
Investments
Details Hidden

Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.

Details Hidden

Avaxia Biologics, Inc. operated as a clinical-stage biotechnology company. It engaged in the development of gut-targeted antibody therapeutics for gastroenterology indications. Gut-targeted antibody therapeutics is orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. The company was founded by David Poorvin and Barbara S. Fox in 2005 and was headquartered in Lexington, MA.

Details Hidden

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.

Suppliers
Galapagos NV Medical Support Services | Mechelen, BU

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Neurocrine Biosciences Inc. Hospitals & Patient Services | SAN DIEGO, CA

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Seattle Genetics, Inc. Pharmaceuticals | Bothell, WA

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Awards & Honors
Rank #123
2016
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
Rank #123
2016
Fortune Magazine - Fortune 500 Companies
Sponsored by Fortune Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by AbbVie, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of AbbVie, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and AbbVie, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/abbvie-inc-25236906
  • https://relationshipscience.com/organization/abbvie-inc-25236906